Table 3.
Predictors of 60-day after ICU admission mortality in the HIV cohort from OutcomeRea™
| Alive at D60 (n = 495) |
Dead at D60 (n = 135) |
Univariate | Multivariate | |||
|---|---|---|---|---|---|---|
| HR, CI 95% | p value | HR, CI 95% | p value | |||
| Age (years) | ||||||
| < 38 | 126 (25.5%) | 29 (21.5%) | Ref. | 0.010 | Ref. | 0.029 |
| 38 to 54 | 249 (50.4%) | 57 (42.2%) | 0.96 [0.61; 1.50] | 0.87 [0.54; 1.39] | ||
| > 54 | 119 (24.1%) | 49 (36.3%) | 1.68 [1.06; 2.67] | 1.47 [0.91; 2.36] | ||
| Katz independence scale | 6 [6; 6] | 6 [6; 6] | 0.95 [0.76; 1.19] | 0.677 | ||
| Sex (male) | 333 (67.4%) | 107 (79.3%) | 1.70 [1.11; 2.58] | 0.013 | 1.33 [0.85; 2.07] | 0.206 |
| Diabetes | 37 (7.5%) | 11 (8.1%) | 1.09 [0.59; 2.02] | 0.786 | ||
| Obesity | 29 (5.9%) | 5 (3.7%) | 0.67 [0.27; 1.63] | 0.375 | ||
| Chronic disease (KNAUS) | ||||||
| Hepatic | 32 (6.5%) | 15 (11.1%) | 1.66 [0.97; 2.85] | 0.066 | 2.07 [1.15; 3.73] | 0.015 |
| Cardiovascular | 35 (7.3%) | 10 (7.4%) | 1.07 [0.56; 2.03] | 0.846 | ||
| Renal | 29 (5.9%) | 12 (8.9%) | 1.59 [0.87; 2.88] | 0.128 | ||
| Respiratory | 36 (7.3%) | 7 (5.2%) | 0.77 [0.36; 1.66] | 0.507 | ||
| Solid neoplasia | 17 (3.4%) | 6 (4.4%) | 1.23 [0.54; 2.80] | 0.619 | ||
| History of chemotherapy | 52 (10.5%) | 39 (28.9%) | 3.09 [2.04; 4.68] | < 0.001 | 2.48 [1.54; 4.00] | < 0.001 |
| Inclusion period | ||||||
| 1(1997–2006) | 167 (33.8%) | 48 (35.6%) | Ref. | 0.929 | Ref. | 0.578 |
| 2(2007–2015) | 263 (53.2%) | 72 (53.3%) | 0.93 [0.63; 1.38] | 0.81 [0.54; 1.22] | ||
| 3(2016–2020) | 64 (13%) | 15 (11.1%) | 1.00 [0.55; 1.82] | 0.82 [0.44; 1.53] | ||
| Medical reason for ICU admission | 467 (94.7%) | 123 (91.1%) | 0.61 [0.33; 1.12] | 0.110 | ||
| Main symptom on admission | ||||||
| Shock | 96 (19.4%) | 33 (24.4%) | 1.28 [0.79; 2.07] | |||
| Acute respiratory distress | 184 (37.2%) | 42 (31.2%) | 0.93 [0.59; 1.47] | |||
| Coma | 82 (16.6%) | 27 (20%) | 1.31 [0.78; 2.18] | |||
| Other | 133 (26.7%) | 33 (24.4%) | Ref. | 0.392 | ||
| SOFA upon ICU admission > 4 | 262 (53%) | 104 (77%) | 2.60 [1.73; 3.88] | < 0.001 | 2.35 [1.56; 3.56] | < 0.001 |
| Pre-ICU hospitalization stay > 24 h | 172 (34.8%) | 72 (53%) | 1.92 [1.36; 2.70] | < 0.001 | 1.47 [1.03; 2.11] | 0.033 |
| AIDS | 355 (71.9%) | 112 (83%) | 1.77 [1.12; 2.80] | 0.014 | 1.79 [1.11; 2.89] | 0.017 |
| HIV status (n = 528) | ||||||
| De novo | 63 (15.1%) | 15 (13.6%) | Ref. | 0.613 | ||
| Known, uncontrolled | 113 (27%) | 26 (23.7%) | 1.20 [0.68; 2.12] | |||
| Known, controlled | 242 (57.9%) | 69 (62.7%) | 0.98 [0.52; 1.86] | |||
| Duration of HIV progression > 10 years (n = 409) | 166 (51.7%) | 40 (45.4%) | 0.82 [0.54; 1.26] | 0.375 | ||
| Last CD4 count > 250/mm3 (n = 282) | 109 (22.1%) | 35 (25.9%) | 1.58 [0.92; 2.70] | 0.096 | ||
| < 50 | 3 (1.5%) | 3 (6.1%) | 1.63 [0.80; 3.35] | |||
| 50 to 200 | 60 (30.8%) | 20 (40.8%) | 1.59 [0.88; 2.85] | |||
| > 200 | 132 (67.7%) | 26 (53.1%) | Ref. | |||
| Last HIV viral load > 2 Log (n = 260) | 107 (50.7%) | 22 (44.9%) | 0.78 [0.44; 1.38] | 0.394 | ||
| ART at ICU admission (n = 531) | 244 (58%) | 69 (62.7%) | 1.21 [0.82; 1.79] | 0.329 | ||
| History of AIDS-classifying condition | ||||||
| Infection | 155 (36.8%) | 53 (48.2%) | 1.47 [1.00; 2.17] | 0.048 | ||
| Hematologic disease | 54 (12.8%) | 20 (18.2%) | 1.18 [0.69; 2.01] | 0.541 | ||
| Diagnosis admission according to HIV/AIDS | ||||||
| AIDS-classifying condition | 145 (34.4%) | 53 (48.2%) | ||||
| Active opportunistic infections | 105 (24.9%) | 29 (26.4%) | 0.98 [0.65; 1.49] | 1.39 [0.81; 2.39] | ||
| Active hemopathy | 96 (22.8%) | 50 (45.5%) | 2.59 [1.68; 3.98] | 1.52 [0.94; 2.46] | ||
| HANA | 43 (10.2%) | 16 (14.5%) | 1.90 [1.06; 3.39] | 1.49 [0.84; 2.64] | ||
| Not associated with HIV | 233 (55.3%) | 41 (37.3%) | Ref. | 0.010 | Ref. | 0.203 |
| ART management in ICU (n = 316) | ||||||
| Suspension | 73 (28.1%) | 21 (38.2%) | 0.98 [0.58; 1.66] | 0.942 | ||
| Resume | 20 (7.7%) | 0 | – | – | ||
| Continued | 167 (64.5%) | 33 (57.9%) | 0.51 [0.32; 0.83] | 0.006 | ||
| Introduction | 22 (8.6%) | 4 (7.3%) | 0.70 [0.21; 2.27] | 0.550 | ||
| Mechanical ventilation during the ICU stay | 179 (36.2%) | 108 (80%) | 5.98 [3.91; 9.14] | < 0.001 | ||
| Vasopressor during the ICU stay | 113 (22.9%) | 70 (51.8%) | 3.08 [2.19; 4.34] | < 0.001 | ||
| RRT during the ICU stay | 71 (14.4%) | 48 (35.6%) | 2.84 [1.98; 4.06] | < 0.001 | ||
| Use of anticancer chemotherapy during the ICU stay | 25 (5.1%) | 16 (11.8%) | 2.22 [1.27; 3.91] | 0.005 | ||
Bold indicates the significance of the result (p < 0.05)
AIDS acquired immunodeficiency syndrome, ART antiretroviral therapy, HANA HIV-associated non-AIDS, HIV human immunodeficiency virus, ICU intensive care unit, RRT renal replacement therapy, SOFA sepsis-related organ failure assessment